Renal Vein Thrombosis After Open Repair of Abdominal Aortic Aneurysm Successfully Treated by Direct Oral Anticoagulants

Date, Yusuke; Nagamine, Hiroshi; Hara, Hiroiku; Kawase, Yushi

doi:10.1177/1538574419839251

Cited by 5 publications

(5 citation statements)

References 3 publications

(7 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Three patients with RVT treated with the DOACs were included in the study by Janczak et al 10 evaluating the use of the DOACs in unusual site VTE. Furthermore, there are four published case reports evaluating the use of rivaroxaban, 99,100 apixaban 101 or edoxaban 102 in patients with RVT with good clinical outcomes. However, the DOACs should be used with caution in patients with RVT due to their risk of accumulation in renal insufficiency.…”

Section: Renal Vein Thrombosismentioning

confidence: 99%

Direct oral anticoagulants for unusual‐site venous thromboembolism

Riva

Ageno

2021

Research and Practice in Thrombosis and Haemostasis

View full text Add to dashboard Cite

Direct oral anticoagulants (DOACs) are currently the preferred oral anticoagulant treatment for most of the patients with deep vein thrombosis of the lower extremities and/or pulmonary embolism. DOACs have several advantages over vitamin K antagonists, such as availability of fixed dosages, fewer drug interactions, faster onset of action, shorter half‐life, and lower risk of major and intracranial bleeding. Although the evidence on the use of DOACs in patients with unusual‐site venous thromboembolism (VTE) is limited to a few, small randomized controlled trials, these drugs are increasingly used in clinical practice, and several observational cohort studies have been published recently. This narrative review will describe the latest evidence for the use of the DOACs in patients with thrombosis in atypical locations (splanchnic, cerebral, upper extremity, ovarian, and renal vein thrombosis) and will provide some practical advice for their use in patients with unusual‐site VTE.

show abstract

Section: Renal Vein Thrombosismentioning

confidence: 99%

Direct oral anticoagulants for unusual‐site venous thromboembolism

Riva

Ageno

2021

Research and Practice in Thrombosis and Haemostasis

View full text Add to dashboard Cite

show abstract

“…Only 4 cases of RVT treated with DOACs (rivaroxaban and apixaban) have been reported so far, with no evidence of increased risk of bleeding or recurrence. 62,95 There is still no experience with DOACs in the treatment of RVO, and their use is discouraged. The only prospective study comparing the use of DOACs (rivaroxaban or apixaban) in patients with thrombosis at unusual sites, including CVST, SVT, OVT, and RVT, and in those with thrombosis at common sites showed comparable safety and efficacy; moreover, the rates of bleeding and recurrent thrombosis in patients treated with DOACs were similar to those in patients treated with enoxaparin.…”

Section: Role Of Doacsmentioning

confidence: 99%

Treatment of unusual thrombotic manifestations

Abbattista¹,

Capecchi

Martinelli

2020

Blood

View full text Add to dashboard Cite

Venous thrombosis rarely occurs at unusual sites such as cerebral, splanchnic, upper-extremity, renal, ovarian, or retinal veins. Clinical features, symptoms, and risk factors of rare thrombotic manifestations are heterogeneous and in large part differ from those typical of the commonest manifestations of venous thrombosis at the lower extremities. The therapeutic approach also varies widely according to the affected site, whether cerebral, abdominal, or extraabdominal. To date, anticoagulant therapy for thrombosis at unusual sites is generally accepted, but the optimal therapeutic approach remains challenging. This review is focused on the treatment of unusual thrombotic manifestations as reported in the most recent guidelines and according to the updated scientific literature.

show abstract

“…Similar to previous literature, most of our patients had underlying malignancy and left renal vein was more commonly affected than the right renal vein. Favorable outcomes with DOAC were also reported in case reports of a patient with isolated RVT 7 and 3 patients with RVT and concomitant pulmonary embolism. 8–10 However, none of the patients in these case reports had underlying malignancy.…”

mentioning

confidence: 61%